United States & Revolution Medicines
5 shared events · Importance 3 · Last updated Aug 27, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
United States: The United States>>> was the location of the U.S.-led study of daraxonrasib and the initial application for drug licensing to the United States — Food and Drug Administration>>>.
Revolution Medicines: Revolution Medicines developed daraxonrasib, the experimental drug that has shown significant promise in treating advanced pancreatic cancer, leading to increased attention and potential for market growth for the company.
May 29, 2026 · 74 articles
Regulatory
United States: The United States, through the FDA, approved the drug, making it available to American patients and potentially influencing global regulatory decisions.
Revolution Medicines: Revolution Medicines received FDA approval for its lead drug daraxonrasib (Rasonque), a first-in-class RAS inhibitor. The approval is expected to drive substantial revenue growth, with analysts projecting up to $11.5 billion in annual sales, and the company's stock has risen 166% this year.
Aug 26, 2026 · 92 articles
Tech
United States: US patients gain a new treatment option for a leading cause of cancer death, with roughly 67,000 new cases and 52,000 deaths annually.
Revolution Medicines: Secures first approval and commercial launch of daraxonrasib under the Rasonque brand at about $39,800 per month, validating its KRAS molecular glue platform and opening expansion into other cancers.
Aug 26, 2026 · 6 articles
International
United States: The United States>>> is a key participant in the Middle East conflict, engaging in military actions and peace negotiations with Iran>>>. Its actions directly influence the stability of the region and global oil prices.
Revolution Medicines: Revolution Medicines is the maker of daraxonrasib, an experimental pill showing promise for advanced pancreatic cancer, and plans to seek United States — Food and Drug Administration approval.
May 18, 2026 · 316 articles
Tech
United States: The guideline is relevant to U.S. healthcare, potentially affecting treatment patterns and costs for pancreatic cancer patients.
Revolution Medicines: The guideline highlights the potential of RAS inhibitors like daraxonrasib, which could expand the market for Revolution Medicines' drug and boost its stock.
Aug 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Revolution Medicines interact across events, view sentiment trends, and discover connected entities.
Open Dashboard